AstraZeneca PLC announces the approval of Datroway for advanced EGFR-mutated lung cancer, highlighting clinical trial success and strategic collaboration with Daiichi Sankyo.
Discover how AstraZeneca's Imfinzi, approved for resectable NSCLC, offers new hope with a 32% reduced recurrence risk, transforming patient care in Europe.
AstraZeneca's Imfinzi receives EU approval as the first immunotherapy for LS-SCLC, showing significant survival benefits. This landmark decision highlights advancements in cancer care.
Explore AstraZeneca's recent MAA withdrawal for datopotamab deruxtecan, ongoing trials, and strategies in advancing lung cancer therapies.